485 related articles for article (PubMed ID: 28838685)
1. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
3. Dose selection for glycopyrrolate/eFlow
Donohue JF; Goodin T; Tosiello R; Wheeler A
Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Ohar J; Tosiello R; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
[TBL] [Abstract][Full Text] [Related]
5. Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
Kerwin EM; Donohue JF; Ferguson GT; Ganapathy V; Ozol-Godfrey A; Rajagopalan K
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):24-33. PubMed ID: 30457433
[TBL] [Abstract][Full Text] [Related]
6. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
Kerwin EM; Murray L; Niu X; Dembek C
Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
[TBL] [Abstract][Full Text] [Related]
7. Effect of background long-acting beta
Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies.
Ferguson GT; Kerwin EM; Donohue JF; Ganapathy V; Tosiello RL; Bollu VK; Rajagopalan K
Chronic Obstr Pulm Dis; 2018 Jun; 5(3):193-207. PubMed ID: 30584583
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
Donohue JF; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():745-754. PubMed ID: 32341641
[TBL] [Abstract][Full Text] [Related]
11. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
[TBL] [Abstract][Full Text] [Related]
12. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
16. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
17. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
18. Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Tashkin DP; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():945-955. PubMed ID: 33880019
[TBL] [Abstract][Full Text] [Related]
19. An overview of glycopyrrolate/eFlow® CS in COPD.
Kerwin E; Ferguson GT
Expert Rev Respir Med; 2018 Jun; 12(6):447-459. PubMed ID: 29774778
[TBL] [Abstract][Full Text] [Related]
20. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
